China Medical System (0867.HK): Accelerating Development and Stepping to a New Height Driven by Innovation
By Gelonghui
HONG KONG, 2021年04月03日 - (JCN Newswire) - As the earning season approaches, once again listed pharmaceutical companies are attracting the attention of the public. Recently, China Medical System Holdings Limited ( CMS or the Company ) has released its annual results, with both revenue and profit higher than market expectations. According to its 2020 annual results, turnover is up by 14.4% to RMB6.946 billion; net profit up by 30.7% to RMB2.556 billion; basic earnings per share up to RMB1.024, with a proposed final dividend of RMB0.20 per share.
In the past, influenced by expectations of the effects of China s centralized procurement policy and the Company s product transition, CMS s valuation in the capital market was once under pressure, but with the Company s strategic transformation from a CSO to an innovative pharmaceutical company, coupled with its o